HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Matthew Caufield has reiterated a 'Buy' rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a $36 price target.
July 31, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on 4D Molecular Therapeutics and maintained a $36 price target.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for the stock. The maintained price target of $36 indicates the firm's continued confidence in the company's potential. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100